Insmed.
company in Bridgewater, United States
- Reports this week
- 0
- Active events
- 0
- Connections
- 42
What's happening
One to three months ago
Gone quiet
No new reports in 90+ days-
Encore supports Insmed's franchise growth.Some support1 report
-
Jim Cramer labeled Insmed as a very speculative investment on July 15, 2025.Some support1 report
-
Insmed established a new R&D hub in Cambridge on July 28, 2025. The company also noted a connection between a key individual and AstraZeneca.Some support1 report
-
Zacks model provides insight into business conditions for Insmed.Some support1 report
-
Insmed reported that revenue from Europe and the rest of the world increased by 48.3% on August 7, 2025.Some support1 report1 development inside
-
Insmed is projected to generate revenue in Europe and Japan.Well supported3 reports
-
Insmed shares added 61.2% on August 7, 2025, significantly outpacing the S&P 500's 7.9% gain.Some support3 reports
-
The FDA approved Insmed's BRINSUPRI therapy on August 26, 2025, noting market comparisons between the US and EU4 markets.Well supported4 reports
-
Barchart provided technical buy signals for Insmed on August 19, 2025.Some support1 report
-
FDA approved BRINSUPRI as first treatment for non-cystic fibrosis bronchiectasis. Insmed application accepted in Japan for BRINSUPRI.Well supported5 reports
No events began in the chosen period. Widen it, or reset.
Around Insmed this week
News at the entities that move Insmed most-
FDA StructuralFDA removed warnings from HRT products, and a meeting is scheduled in Chicago involving researchers from Clalit Health Services.Moves Insmed
-
Morgan Stanley Mentioned togetherRBA rate hikes are affecting the market outlook for Australian companies, including SGH Ltd, whose value is being analyzed by Morgan Stanley.Moves Insmed
-
Goldman Sachs OperationalTaft-Vazquez is running in the Santa Barbara City Council District 4 race, having previously worked at Goldman Sachs and Coca-Cola.Moves Insmed
-
Leerink partners TransactionalIllumina and Leerink partners are involved in a new development.Moves Insmed
-
Nasdaq StructuralTaiwan aims to transform its capital market into an Asian Nasdaq, positioning Taipei as a major financial hub.Moves Insmed
-
Europe Shared contextRussia's gas imports to Europe decreased significantly as the Middle East conflict drives up gas prices.Moves Insmed
Connections
The 9 strongest of 42, analyzed from the reporting. The bars show how strongly a change on one side reaches the other.-
FDA Structural
Insmed's ability to market its drugs is structurally dependent on formal regulatory review and approval by the FDA.
-
PPF Operational
Insmed and PPF are engaged in a partnership related to Insmed's planned Phase III clinical studies.
-
United Therapeutics Operational
The companies actively compete in PAH treatments while Insmed supplies a critical prodrug component for United Therapeutics' drug.
-
Goldman Sachs Operational
Goldman Sachs provides financial analysis and coverage for Insmed, which presents to the firm.
-
Nasdaq Structural
Insmed operates as a listed company on the Nasdaq stock exchange.
-
Encore Structural
Encore provides functional support critical to Insmed's continued franchise growth.
-
Morgan Stanley Mentioned together
Morgan Stanley provided investment recommendations and raised price targets for Insmed stock.
-
Leerink partners Transactional
Leerink Partners acted as a joint book-running manager for Insmed during a financial offering.
Show all 9 connections
-
Europe Shared context
Insmed operates and generates revenue within the European market, utilizing offices and research locations across the continent.
History
Events by the month they beganAugust 2026
1 eventJune 2026
10 events- Encore supports Insmed's franchise growth.
- Jim Cramer labeled Insmed as a very speculative investment on July 15, 2025.
- Insmed established a new R&D hub in Cambridge on July 28, 2025. The company also noted a connection between a key individual and AstraZeneca.
- Zacks model provides insight into business conditions for Insmed.
- Insmed reported that revenue from Europe and the rest of the world increased by 48.3% on August 7, 2025.
- Insmed is projected to generate revenue in Europe and Japan.
- Insmed shares added 61.2% on August 7, 2025, significantly outpacing the S&P 500's 7.9% gain.
- The FDA approved Insmed's BRINSUPRI therapy on August 26, 2025, noting market comparisons between the US and EU4 markets.
- Barchart provided technical buy signals for Insmed on August 19, 2025.
- FDA approved BRINSUPRI as first treatment for non-cystic fibrosis bronchiectasis. Insmed application accepted in Japan for BRINSUPRI.